Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa 80,000 Units Q3W in Anemic Cancer Patients
NCT00210587Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2005
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
A Phase 3 trial of epoetin alfa in anemia, sponsored by Johnson & Johnson. Started Feb 2005; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00210587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210587.